



NeuroStabilene™

**Designed for the brain. Built for
Alzheimer's**

Sector: Biotech / Neurodegeneration / Therapeutics

IP Status: Provisional Patent Filed – May 2025

Availability: Licensing | Strategic Partnership | Acquisition

Key Applications:

- Disease-modifying therapy for Alzheimer's, frontotemporal dementia (FTD), and tauopathies
- Tau-targeted neurotherapeutic with lysosomal clearance mechanism
- Intranasal or sublingual delivery across the blood–brain barrier (BBB)
- Platform chemistry adaptable for Parkinson's, TBI, and long-COVID neuro-sequelae

NeuroStabilene™ is a novel therapeutic platform engineered for selective tau inhibition and targeted intracellular clearance across the blood–brain barrier. Designed to address the core pathology of Alzheimer's and related tauopathies, it delivers precision degradation through a multi-domain conjugate architecture that activates only after target engagement. Unlike current tau-targeting approaches, NeuroStabilene™ combines BBB permeability, high-affinity selectivity, and an inducible degradation mechanism—enabling non-toxic, disease-modifying treatment via intranasal or sublingual administration.

Start a Collaboration: info@whitakersyndicates.com